Independent register of U.S. FDA drug recalls · updated Oct 13, 2026
RxRecalls Get alerts

Class II drug recalls - moderate risk

Class II means the product may cause temporary or medically reversible harm, and serious harm is unlikely. It is by far the largest recall class - most potency, dissolution and labeling problems land here.

14,543 recalls, newest first.

Class II · Moderate risk

Midazolam

Stability data does not support expiry.

Terminated Stability / shelf life Pharmakon Pharmaceuticals D-0595-2016
Class II · Moderate risk

Mupirocin Calcium Cream

Penicillin Cross Contamination and Presence of Foreign Substance. Product was contaminated with penicillin and foreign substances during manufacturing process.

Terminated Cross-contamination GlaxoSmithKline, LLC. NDC 66993-942-15 D-1362-2015
Class II · Moderate risk

Bactroban Cream

Penicillin Cross Contamination and Presence of Foreign Substance. Product was contaminated with penicillin and foreign substances during manufacturing process.

Terminated Cross-contamination GlaxoSmithKline, LLC. NDC 0029-1527-22 D-1361-2015
Class II · Moderate risk

Bactroban Ointment

Penicillin Cross Contamination and Presence of Foreign Substance. Product was contaminated with penicillin and foreign substances during manufacturing process.

Terminated Cross-contamination GlaxoSmithKline, LLC. NDC 0029-1525-44 D-1360-2015
Class II · Moderate risk

Bactroban (mupirocin calcium)

Penicillin Cross Contamination and Presence of Foreign Substance. Product was contaminated with penicillin and foreign substances during manufacturing process.

Terminated Cross-contamination GlaxoSmithKline, LLC. NDC 0029-1526-11 D-1359-2015
Class II · Moderate risk

Midazolam HCl Syrup

Presence of Foreign Substance: customer complaint that one unit dose cup contained a small piece of cardboard contaminant.

Terminated Particulate / foreign matter Safecor Health, LLC D-0657-2016
Class II · Moderate risk

Lisinopril Tablets

Failed Dissolution Specifications

Terminated Dissolution failure Vintage Pharmaceuticals LLC dba Qualitest Pharmaceuticals NDC 0603-4214-60 D-1406-2015
Class II · Moderate risk

Lisinopril Tablets USP

CGMP Deviations: An FDA inspection identified inadequate investigations of past market complaints.

Terminated cGMP deviation Wockhardt Usa Inc. NDC 64679-941-06 D-1347-2015
Class II · Moderate risk

Lisinopril Tablets USP

CGMP Deviations: An FDA inspection identified inadequate investigations of past market complaints.

Terminated cGMP deviation Wockhardt Usa Inc. NDC 64679-928-06 D-1346-2015

Recalls by year